| Segment / region | Type | Fiscal year | Currency | Revenue (millions) | Share of revenue |
|---|---|---|---|---|---|
| UNITED STATES | Region | 2025 | USD | 46,603.0 | 95.2% |
| Non-US | Region | 2025 | USD | 2,364.0 | 4.8% |
| UNITED STATES | Region | 2024 | USD | 43,029.0 | 76.4% |
| Non-US | Region | 2024 | USD | 13,305.0 | 23.6% |
| UNITED STATES | Region | 2023 | USD | 41,883.0 | 77.1% |
| Non-US | Region | 2023 | USD | 12,435.0 | 22.9% |
| UNITED STATES | Region | 2022 | USD | 45,713.0 | 78.7% |
| Non-US | Region | 2022 | USD | 12,341.0 | 21.3% |
| UNITED STATES | Region | 2021 | USD | 43,510.0 | 77.4% |
| Non-US | Region | 2021 | USD | 12,687.0 | 22.6% |
| UNITED STATES | Region | 2020 | USD | 34,879.0 | 76.2% |
| Non-US | Region | 2020 | USD | 10,925.0 | 23.9% |
| SKYRIZI | Product | 2025 | USD | 17,562.0 | 30.2% |
| RINVOQ | Product | 2025 | USD | 8,304.0 | 14.3% |
| H U M I R A | Product | 2025 | USD | 4,540.0 | 7.8% |
| Botox Therapeutic | Product | 2025 | USD | 3,769.0 | 6.5% |
| Vraylar | Product | 2025 | USD | 3,621.0 | 6.2% |
| Imbruvica | Product | 2025 | USD | 2,869.0 | 4.9% |
| VENCLEXTA | Product | 2025 | USD | 2,792.0 | 4.8% |
| Other Products | Product | 2025 | USD | 2,627.0 | 4.5% |
| Botox Cosmetic | Product | 2025 | USD | 2,602.0 | 4.5% |
| MAVYRET | Product | 2025 | USD | 1,317.0 | 2.3% |
| Ubrelvy | Product | 2025 | USD | 1,271.0 | 2.2% |
| Other Aesthetics | Product | 2025 | USD | 1,265.0 | 2.2% |
| Qulipta | Product | 2025 | USD | 1,036.0 | 1.8% |
| Other Eye Care | Product | 2025 | USD | 1,009.0 | 1.7% |
| Juvederm Collection | Product | 2025 | USD | 993.0 | 1.7% |
| Linzess/Constella | Product | 2025 | USD | 907.0 | 1.6% |
| Ozurdex | Product | 2025 | USD | 493.0 | 0.9% |
| Lumigan/Ganfort | Product | 2025 | USD | 410.0 | 0.7% |
| Duodopa | Product | 2025 | USD | 381.0 | 0.7% |
| Other Neuroscience | Product | 2025 | USD | 207.0 | 0.4% |
| Alphagan/Combigan | Product | 2025 | USD | 197.0 | 0.3% |
| SKYRIZI | Product | 2024 | USD | 11,718.0 | 21.6% |
| H U M I R A | Product | 2024 | USD | 8,993.0 | 16.6% |
| RINVOQ | Product | 2024 | USD | 5,971.0 | 11.0% |
| Imbruvica | Product | 2024 | USD | 3,347.0 | 6.2% |
| Botox Therapeutic | Product | 2024 | USD | 3,283.0 | 6.0% |
| Vraylar | Product | 2024 | USD | 3,267.0 | 6.0% |
| Other Products | Product | 2024 | USD | 3,032.0 | 5.6% |
| Botox Cosmetic | Product | 2024 | USD | 2,720.0 | 5.0% |
| VENCLEXTA | Product | 2024 | USD | 2,583.0 | 4.8% |
| MAVYRET | Product | 2024 | USD | 1,311.0 | 2.4% |
| Other Aesthetics | Product | 2024 | USD | 1,279.0 | 2.4% |
| Juvederm Collection | Product | 2024 | USD | 1,177.0 | 2.2% |
| Ubrelvy | Product | 2024 | USD | 1,006.0 | 1.9% |
| Linzess/Constella | Product | 2024 | USD | 954.0 | 1.8% |
| Other Eye Care | Product | 2024 | USD | 847.0 | 1.6% |
| Qulipta | Product | 2024 | USD | 658.0 | 1.2% |
| Ozurdex | Product | 2024 | USD | 494.0 | 0.9% |
| Duodopa | Product | 2024 | USD | 447.0 | 0.8% |
| Lumigan/Ganfort | Product | 2024 | USD | 429.0 | 0.8% |
| Other Neuroscience | Product | 2024 | USD | 338.0 | 0.6% |
| Alphagan/Combigan | Product | 2024 | USD | 248.0 | 0.5% |
| Restasis | Product | 2024 | USD | 224.0 | 0.4% |
| H U M I R A | Product | 2023 | USD | 14,404.0 | 27.2% |
| SKYRIZI | Product | 2023 | USD | 7,763.0 | 14.6% |
| RINVOQ | Product | 2023 | USD | 3,969.0 | 7.5% |
| Imbruvica | Product | 2023 | USD | 3,596.0 | 6.8% |
| Other Products | Product | 2023 | USD | 3,035.0 | 5.7% |
| Botox Therapeutic | Product | 2023 | USD | 2,991.0 | 5.6% |
| Vraylar | Product | 2023 | USD | 2,759.0 | 5.2% |
| Botox Cosmetic | Product | 2023 | USD | 2,682.0 | 5.1% |
| VENCLEXTA | Product | 2023 | USD | 2,288.0 | 4.3% |
| MAVYRET | Product | 2023 | USD | 1,430.0 | 2.7% |
| Juvederm Collection | Product | 2023 | USD | 1,378.0 | 2.6% |
| Other Aesthetics | Product | 2023 | USD | 1,234.0 | 2.3% |
| Linzess/Constella | Product | 2023 | USD | 1,108.0 | 2.1% |
| Ubrelvy | Product | 2023 | USD | 815.0 | 1.5% |
| Other Eye Care | Product | 2023 | USD | 803.0 | 1.5% |
| Ozurdex | Product | 2023 | USD | 472.0 | 0.9% |
| Duodopa | Product | 2023 | USD | 468.0 | 0.9% |
| Restasis | Product | 2023 | USD | 436.0 | 0.8% |
| Lumigan/Ganfort | Product | 2023 | USD | 432.0 | 0.8% |
| Qulipta | Product | 2023 | USD | 408.0 | 0.8% |
| Other Neuroscience | Product | 2023 | USD | 276.0 | 0.5% |
| Alphagan/Combigan | Product | 2023 | USD | 272.0 | 0.5% |
| H U M I R A | Product | 2022 | USD | 21,237.0 | 38.0% |
| SKYRIZI | Product | 2022 | USD | 5,165.0 | 9.2% |
| Imbruvica | Product | 2022 | USD | 4,568.0 | 8.2% |
| Other Products | Product | 2022 | USD | 4,137.0 | 7.4% |
| Botox Therapeutic | Product | 2022 | USD | 2,719.0 | 4.9% |
| Botox Cosmetic | Product | 2022 | USD | 2,615.0 | 4.7% |
| RINVOQ | Product | 2022 | USD | 2,522.0 | 4.5% |
| Vraylar | Product | 2022 | USD | 2,038.0 | 3.6% |
| VENCLEXTA | Product | 2022 | USD | 2,009.0 | 3.6% |
| MAVYRET | Product | 2022 | USD | 1,541.0 | 2.8% |
| Juvederm Collection | Product | 2022 | USD | 1,428.0 | 2.6% |
| Other Aesthetics | Product | 2022 | USD | 1,290.0 | 2.3% |
| Other Eye Care | Product | 2022 | USD | 1,175.0 | 2.1% |
| Linzess/Constella | Product | 2022 | USD | 1,035.0 | 1.9% |
| Restasis | Product | 2022 | USD | 666.0 | 1.2% |
| Lumigan/Ganfort | Product | 2022 | USD | 514.0 | 0.9% |
| Other Neuroscience | Product | 2022 | USD | 475.0 | 0.9% |
| Duodopa | Product | 2022 | USD | 458.0 | 0.8% |
| Alphagan/Combigan | Product | 2022 | USD | 346.0 | 0.6% |
| H U M I R A | Product | 2021 | USD | 20,694.0 | 41.1% |
| Imbruvica | Product | 2021 | USD | 5,408.0 | 10.7% |
| SKYRIZI | Product | 2021 | USD | 2,939.0 | 5.8% |
| Other Products | Product | 2021 | USD | 2,673.0 | 5.3% |
| Botox Therapeutic | Product | 2021 | USD | 2,451.0 | 4.9% |
| Botox Cosmetic | Product | 2021 | USD | 2,232.0 | 4.4% |
| VENCLEXTA | Product | 2021 | USD | 1,820.0 | 3.6% |
| MAVYRET | Product | 2021 | USD | 1,710.0 | 3.4% |
| RINVOQ | Product | 2021 | USD | 1,651.0 | 3.3% |
| Juvederm Collection | Product | 2021 | USD | 1,535.0 | 3.1% |
| Other Aesthetics | Product | 2021 | USD | 1,466.0 | 2.9% |
| Restasis | Product | 2021 | USD | 1,290.0 | 2.6% |
| Other Eye Care | Product | 2021 | USD | 1,169.0 | 2.3% |
| Linzess/Constella | Product | 2021 | USD | 1,038.0 | 2.1% |
| Other Neuroscience | Product | 2021 | USD | 685.0 | 1.4% |
| Lumigan/Ganfort | Product | 2021 | USD | 579.0 | 1.2% |
| Alphagan/Combigan | Product | 2021 | USD | 529.0 | 1.1% |
| Duodopa | Product | 2021 | USD | 511.0 | 1.0% |
| H U M I R A | Product | 2020 | USD | 19,832.0 | 47.9% |
| Imbruvica | Product | 2020 | USD | 5,314.0 | 12.8% |
| Other Products | Product | 2020 | USD | 2,923.0 | 7.1% |
| MAVYRET | Product | 2020 | USD | 1,830.0 | 4.4% |
| SKYRIZI | Product | 2020 | USD | 1,590.0 | 3.8% |
| Botox Therapeutic | Product | 2020 | USD | 1,387.0 | 3.4% |
| VENCLEXTA | Product | 2020 | USD | 1,337.0 | 3.2% |
| Botox Cosmetic | Product | 2020 | USD | 1,112.0 | 2.7% |
| Restasis | Product | 2020 | USD | 787.0 | 1.9% |
| Other Aesthetics | Product | 2020 | USD | 760.0 | 1.8% |
| RINVOQ | Product | 2020 | USD | 731.0 | 1.8% |
| Juvederm Collection | Product | 2020 | USD | 718.0 | 1.7% |
| Other Eye Care | Product | 2020 | USD | 693.0 | 1.7% |
| Linzess/Constella | Product | 2020 | USD | 667.0 | 1.6% |
| Other Neuroscience | Product | 2020 | USD | 539.0 | 1.3% |
| Duodopa | Product | 2020 | USD | 494.0 | 1.2% |
| Lumigan/Ganfort | Product | 2020 | USD | 378.0 | 0.9% |
| Alphagan/Combigan | Product | 2020 | USD | 326.0 | 0.8% |
Product and geographic breakdowns describe the same revenue from different perspectives and should not be added together.
